Eugenia Opolka-Hoffmann

Statistics

Publications

Citations

H-Index

Active since

2021

Affiliations

Roche (Switzerland)(Current)

Roche Pharma AG (Germany)

Eugenia Opolka-Hoffmann is an author at Roche (Switzerland) specializing in antibody effector functions, anti-drug antibody formation, and immunopharmacology.

Publications per year

2021–2024

Publications

The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance

Eugenia Opolka-Hoffmann, Gregor Jordan, Michael B. Otteneder et al. · mAbs · 2021 · 27 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

Anna Spreafico, Eva Muñoz‐Couselo, Anja Irmisch et al. · Frontiers in Oncology · 2024 · 15 citations · Full text

Life Sciences, Immunology, Oncology +17

Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice

Jérôme Egli, Stefan Heiler, Felix Weber et al. · mAbs · 2022 · 12 citations · Full text

Medicine, Immunology, Oncology +15

1–3 of 3